Jennifer Ellis

Jennifer Ellis is the Senior Vice President of Quality at Venatorx Pharmaceuticals. Jennifer has over 20 years of experience in the pharmaceutical industry, including positions at Protez Pharmaceuticals/Novartis Pharmaceuticals and ViroPharma Incorporated. Jennifer has a proven track record in delivering successful results, leading their team to develop HCV-796 and VP-246, which have both been marketed and stockpiled for the treatment of smallpox. Jennifer is a highly respected member of the pharmaceutical community and their work has helped shape the landscape of modern medicine.

Jennifer Ellis has a Ph.D. in Organic Chemistry from the Massachusetts Institute of Technology and a Bachelor of Science in Chemistry from Saint Joseph's University.

Jennifer Ellis works with Daniel C. Pevear - Founder & SVP, Biology & Grants Development, Tony Meehan - Chief Business Officer, and Greg Moeck - SVP, Microbiology. Jennifer Ellis reports to Christopher J. Burns, Founder, President & CEO.